7-((4-methylpiperazin-1-yl)methyl)-3-(thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole

ID: ALA213743

PubChem CID: 44414347

Max Phase: Preclinical

Molecular Formula: C20H22N4S

Molecular Weight: 350.49

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CN1CCN(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)CC1

Standard InChI:  InChI=1S/C20H22N4S/c1-23-5-7-24(8-6-23)12-14-2-3-15-11-18-19(16-4-9-25-13-16)21-22-20(18)17(15)10-14/h2-4,9-10,13H,5-8,11-12H2,1H3,(H,21,22)

Standard InChI Key:  OLLCPXMBOYVHAF-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 25 29  0  0  0  0  0  0  0  0999 V2000
    6.6630    2.5394    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6617    1.7117    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3747    1.2987    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3728    2.9521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0910    2.5434    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0915    1.7163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8783    1.4612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8773    2.7993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3583    2.1319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1418    2.3830    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1450    3.2058    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.3636    3.4630    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.8074    1.8954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.8017    1.0742    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5853    0.8160    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   12.0730    1.4817    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5906    2.1510    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9482    2.9513    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2341    2.5386    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5185    2.9585    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8067    2.5494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8027    1.7244    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5169    1.3101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2351    1.7208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0868    1.3142    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
 11 12  1  0
 12  8  1  0
  2  3  1  0
 10 13  1  0
 13 14  2  0
  3  6  2  0
  6  7  1  0
  7  9  1  0
  8  5  1  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
 17 13  1  0
  8  9  2  0
  1 18  1  0
  1  2  2  0
 18 19  1  0
 19 20  1  0
  5  4  2  0
  4  1  1  0
  5  6  1  0
  9 10  1  0
 19 24  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 10 11  2  0
 22 25  1  0
M  END

Associated Targets(Human)

PDGFRB Tclin Platelet-derived growth factor receptor (507 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FLT4 Tclin Vascular endothelial growth factor receptor 3 (3216 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FLT1 Tclin Vascular endothelial growth factor receptor 1 (6262 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KIT Tclin Stem cell growth factor receptor (10667 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TEK Tclin Tyrosine-protein kinase TIE-2 (3348 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FGFR3 Tclin Fibroblast growth factor receptor (331 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
LCK Tclin Tyrosine-protein kinase LCK (9212 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MET Tclin Hepatocyte growth factor receptor (10718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin Vascular endothelial growth factor receptor 2 (20924 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 350.49Molecular Weight (Monoisotopic): 350.1565AlogP: 3.46#Rotatable Bonds: 3
Polar Surface Area: 35.16Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 8.80CX Basic pKa: 7.88CX LogP: 3.21CX LogD: 2.89
Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.61Np Likeness Score: -1.62

References

1. Dinges J, Akritopoulou-Zanze I, Arnold LD, Barlozzari T, Bousquet PF, Cunha GA, Ericsson AM, Iwasaki N, Michaelides MR, Ogawa N, Phelan KM, Rafferty P, Sowin TJ, Stewart KD, Tokuyama R, Xia Z, Zhang HQ..  (2006)  Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors.,  16  (16): [PMID:16750628] [10.1016/j.bmcl.2006.05.052]
2. Dinges J, Ashworth KL, Akritopoulou-Zanze I, Arnold LD, Baumeister SA, Bousquet PF, Cunha GA, Davidsen SK, Djuric SW, Gracias VJ, Michaelides MR, Rafferty P, Sowin TJ, Stewart KD, Xia Z, Zhang HQ..  (2006)  1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.,  16  (16): [PMID:16759855] [10.1016/j.bmcl.2006.05.066]

Source